Q-Line Biotech IPO GMP: Price Band, Dates, Lot Size & Latest Details

The Q-Line Biotech IPO GMP has become a major point of discussion among retail and HNI investors in the SME IPO market. With strong market attention and a sizeable fresh issue, investors are closely tracking the Grey Market Premium (GMP), subscription status, and listing expectations of the IPO.

Q-Line Biotec IPO is a book-built issue worth ₹214.48 crores. The IPO consists entirely of a fresh issue of approximately 0.63 crore shares, helping the company raise funds for future expansion and business growth initiatives.

The IPO subscription window opened on May 21, 2026, and will remain open until May 25, 2026. Investors interested in SME IPO opportunities are actively monitoring the Q-Line Biotech IPO GMP to estimate possible listing gains before the stock debuts on the exchange.

According to the official schedule, the basis of allotment for Q-Line Biotec IPO is expected to be finalized on May 26, 2026. The company is expected to list on the NSE SME platform with a tentative listing date of May 29, 2026.

The company has fixed the IPO price band between ₹326 and ₹343 per share. Investors can bid within this range depending on their market outlook and investment strategy. The IPO lot size has been set at 400 shares per lot, making the minimum retail application size relatively high compared to many SME IPOs.

For retail investors, the minimum investment amount required is approximately ₹2,74,400 for 2 lots or 800 shares at the upper price band. Meanwhile, High Net-Worth Individuals (HNIs) need to apply for a minimum of 3 lots, equivalent to 1,200 shares, requiring an investment of around ₹4,11,600.

The Q-Line Biotech IPO GMP is expected to play an important role in shaping investor sentiment ahead of listing day. GMP trends generally indicate unofficial market demand and investor confidence. However, experts suggest that investors should not rely solely on grey market activity and should also evaluate the company’s financial performance, business model, industry growth potential, and valuation before investing.

SME IPOs have recently attracted strong participation due to the possibility of short-term listing gains. Still, market volatility and liquidity risks remain important factors to consider. Investors are advised to assess risk tolerance carefully before applying.

As the IPO moves closer to allotment and listing, market participants will continue tracking the Q-Line Biotech IPO GMP, subscription figures, and overall investor response for better insights into potential listing performance.